It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing
histone deacetylation. Aberrant expression of HDACs is associated with various human …

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …

Central nervous system (CNS) neurodegenerative diseases are characterized by faulty
intracellular transport, cognition, and aggregate regulation. Traditionally, neuroprotection …

In this study, we report the first highly selective HDAC6 inhibitor with hydrazide as the zinc-
binding group (ZBG), which displays superior pharmacokinetic properties to the current …

Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors
(HDACis) have positioned these agents as promising drug candidates in combatting cancer …

The etiology of autism spectrum disorder (ASD) remains unknown, but gene-environment
interactions, mediated through epigenetic mechanisms, are thought to be a key contributing …

Drug studies on Rett syndrome (RTT) have drastically increased over the past few decades.
This review aims to provide master data on bench-to-bedside drug studies involving RTT. A …

ABSTRACT Introduction: Histone deacetylase 6 (HDAC6) is unique in comparison with other
zinc-dependent HDAC family members. An increasing amount of evidence from clinical and …

Many populations worldwide are suffering from central nervous system (CNS) diseases such
as brain tumors, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease …